NETARSUDIL MESYLATE (netarsudil)
Netarsudil helps patients with open-angle glaucoma or ocular hypertension by lowering elevated pressure within the eye. This medication is used to manage intraocular pressure, which is a key factor in these chronic eye conditions. It provides a therapeutic option for individuals needing to reduce high eye pressure to maintain ocular health.
How NETARSUDIL MESYLATE Works
As a rho kinase inhibitor, this drug works by increasing the drainage of aqueous humor from the eye. It specifically targets the trabecular meshwork to improve fluid outflow, which results in a reduction of intraocular pressure.
Development Insights
Details
- Status
- Prescription
- First Approved
- N/A
- Routes
- DROPS
- Dosage Forms
- SOLUTION
NETARSUDIL MESYLATE Approval History
What NETARSUDIL MESYLATE Treats
2 indicationsNETARSUDIL MESYLATE is approved for 2 conditions . These indications span multiple therapeutic areas including oncology, immunology, and more.
- Open-Angle Glaucoma
- Ocular Hypertension
NETARSUDIL MESYLATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in NETARSUDIL MESYLATE's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications NETARSUDIL MESYLATE treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to NETARSUDIL MESYLATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06449352 | ZV-24-01 | Ph 4 | completed | Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost |
| NCT03971357 results posted | 2018-009 | Ph 2, Ph 3 | terminated | Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration |
| NCT03248037 results posted | 2017-003 | Ph 3 | completed | Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NETARSUDIL MESYLATE FDA Label Details
Indications & Usage
NETARSUDIL MESYLATE is indicated for the treatment of Open-Angle Glaucoma; Ocular Hypertension.
Track NETARSUDIL MESYLATE with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment